Lestaurtinib
From Self-sufficiency
| File:Lestaurtinib.png | |
| Identifiers | |
|---|---|
| ATC code | none |
| PubChem | CID 126565 |
| Chemical data | |
| Formula | C26H21N3O4 |
| Molar mass | 439.462 g/mol[[Script error: No such module "String".]] |
Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine, and is being developed by Cephalon.
It is an inhibitor of FLT3[1], JAK2[2], TrkA, TrkB and TrkC.[3]
Uses
It is undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders.
As of 2008, it is currently in Phase III clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.[4]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Revill, P., Serradell, N., Bolos, J., Rosa, E. (2007). "Lestaurtinib". Drugs of the Future. 32 (3): 215. doi:10.1358/dof.2007.032.03.1084137.
- ↑ Cephalon - Pipeline
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Tyrosine kinase inhibitors
- Lactams
- Pharmacology stubs
- CS1 maint: Multiple names: authors list
